AstraZeneca lung cancer immunotherapy trial failure sends shares plunging – STAT
STAT |
AstraZeneca lung cancer immunotherapy trial failure sends shares plunging
STAT highly anticipated clinical trial combining two immunotherapy drugs failed to delay tumor growth in patients with newly diagnosed lung cancer, sending AstraZeneca sharply lower Thursday. The negative results from the so-called MYSTIC study are a … Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails AstraZeneca shares plunge 16 percent as lung cancer study fails AstraZeneca Lung Cancer Failure Sparks 16 Percent Share Fall |
